Tech Company Financing Transactions
Edison Pharmaceuticals Funding Round
Edison Pharmaceuticals secured a $20 million Series F investment round on 11/27/2012. Investors included Mitsui & Co. and private investors.
Transaction Overview
Company Name
Announced On
11/27/2012
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series F
Investors
Mitsui & Co. (Lead Investor)
Proceeds Purpose
Proceeds will be used to advance the clinical development of EPI-743. The company has recently announced the initiation of phase 2B clinical trials in the United States in two orphan mitochondrial diseases, Leigh syndrome and Friedreich's ataxia. Additional clinical development initiatives are underway and will be announced in Q1 2013.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
350 North Bernardo Ave.
Mountain View, CA 94043
USA
Mountain View, CA 94043
USA
Phone
Website
Email Address
Overview
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Guy Miller
Chief Medical Officer
Matthew Klein
VP - Manufacturing
Peter Giannousis
VP - R & D
Kerstin Leuther
Browse more venture capital transactions:
Prev: 11/27/2012: Bizible venture capital transaction
Next: 11/27/2012: Veenome venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs